Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results

doi:10.12998/wjcc.v9.i18.4559

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 18

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4917)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-5) series.

Item

Count

PDF

318

WORD

159

HTML

2501

Figures (1-4)

484

Tables (1-5)

285

Sum=3747

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

410

Download

760

Sum=1170

Jun 26, 2021 (publication date) through Feb 18, 2025

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Clin Cases. Jun 26, 2021; 9(18): 4559-4572
Published online Jun 26, 2021. doi: 10.12998/wjcc.v9.i18.4559

Table 3 Kaplan-Meier survival analysis according to scores and other systems in cohort 1 (n = 324)

Scoring/Staging systems	OS (95%CI), mo	P value (log-rank)	Sidak¹	Hazard ratio (95%CI)	P value
²Pre-TACE-predict		< 0.0001
Category 1 (n = 47)	38 (30-68)		Ref	Ref
Category 2 (n = 144)	32 (28-36)		0.9707	1.45 (0.96-2.19)	0.0769
Category 3 (n = 109)	18 (16-21)		< 0.0001	2.99 (1.97-4.54)	< 0.0001
Category 4 (n = 23)	11 (8-15)		< 0.0001	4.87 (2.81-8.47)	< 0.0001
²Post-TACE-Predict		< 0.0001
Category 1 (n = 74)	44 (35-66)		Ref	Ref
Category 2 (n = 125)	32 (25-35)		0.0725	1.94 (1.35-2.78)	0.0003
Category 3 (n = 80)	19 (16-24)		< 0.0001	4.33 (2.92-6.41)	< 0.0001
Category 4 (n = 44)	12 (8-13)		< 0.0001	14.0 (8.89-22.15)	< 0.0001
“6 and 12” score		< 0.0001
Sum ≤ 6 (n = 154)	31 (27-35)		Ref	Ref
Sum 6-12 (n = 163)	20 (17-24)		0.0009	1.55 (1.21-1.99)	0.0005
Sum > 12 (n = 7)	15 (5-19)		< 0.0001	3.80 (1.76-8.21)	0.0007
BCLC staging		< 0.0001
A (n = 145)	35 (29-38)		-	Ref
B (n = 179)	19 (17-23)		-	1.88 (1.47-2.41)	< 0.0001
NIACE score		< 0.0001
≤ 1 (n = 168)	35 (28-36)		Ref	Ref
1.5-3 (n = 134)	20 (16-23)		< 0.0001	1.92 (1.49-2.48)	< 0.0001
> 3 (n = 22)	11 (5-16)		< 0.0001	6.23 (3.87-10.02)	< 0.0001
Child-Pugh class		0.0003
A (n = 249)	27 (25-31)		-	Ref
B (n = 75)	21 (15-24)		-	1.66 (1.26-2.19)	0.0003
ALBI grade		0.0029
Grade 1 (n = 64)	35 (25-43)		Ref	Ref
Grade 2 (n = 230)	26 (22-28)		0.1228	1.50 (1.06-2.11)	0.0216
Grade 3 (n = 30)	16 (12-24)		0.0016	2.30 (1.41-3.75)	0.0009

¹Sidak test for multiple comparisons.

²Available data for 323 patients for score calculation. OS: Overall survival; CI: Confidence interval; “6 and 12”: “Six-and-Twelve”; Ref: Reference; BCLC: Barcelona Clinic Liver Cancer; NIACE: Number of tumor(s), Infiltrative hepatocellular carcinoma, Alpha-fetoprotein, Child-Pugh class, Eastern Cooperative Oncology Group Performance Status; ALBI: Albumin-Bilirubin.

Citation: Adhoute X, Larrey E, Anty R, Chevallier P, Penaranda G, Tran A, Bronowicki JP, Raoul JL, Castellani P, Perrier H, Bayle O, Monnet O, Pol B, Bourliere M. Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results. World J Clin Cases 2021; 9(18): 4559-4572
URL: https://www.wjgnet.com/2307-8960/full/v9/i18/4559.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i18.4559